ZOM Zomedica Corp. Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
07:27
Jan 24
Jan 24
Zomedica undervalued on revenue growth, buy
The author, holding 320,000 shares, argues Zomedica is severely undervalued because of revenue growth in 20 consecutive quarters, multiple new products approved with patents, and international distribution agreements. He cites a long coiling bull flag as shorts have been driven out, a CEO public commitment to no more reverse splits, and strong holder resistance to selling. He states he is a buyer.
HIGH
About ZOM Investor Commentary
Across the available history and selected sources, Buzzberg tracks ZOM (Zomedica Corp.) across 1 sources: 1 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Latest voices: u/BigDaddyJohnJohn.